Prostate cancer progression inhibition
Prostate cancer is one of the commonest cancers worldwide. Our research is looking at mechanisms of prostate cancer progression and of treatment resistance, using molecular biology, structural biology and bioinformatics approaches in biomarker discovery as a means of identifying new diagnostic and drug targets. We have taken 2 approaches. Firstly, we have tested novel inhibitors of prostate cancer invasion/metastasis and secondly, we have undertaken a time-course, whole genome analysis of an in vitro model of evolving androgen resistance. These strategies should lead to new diagnostic, prognostic and therapeutic approaches to this common malignancy.
We have identified potential compounds which inhibit prostate cancer progression. The aim of this Honours project is to confirm anti-metastatic potential of these compounds in in vivo mouse models of primary human tumour xenotransplants. In addition, investigation of potential mechanisms of action of these compounds in angiogenesis will be carried out using in vitro tube formation assay.
- Dr Melissa Davis, Bioinformatics Laboratory, Walter and Eliza Hall Institute of Medical Research, VIC, Australia
- Prof Michael Parker, Structural Biology Laboratory, St. Vincent's Institute for Medical Research, VIC, Australia
- Dr Elizabeth Williams, Tumour Model Laboratory, Australian Prostate Cancer Research Center Queensland, QLD, Australia
- Detchokul S, Elangovan A, Crampin EJ, Davis MJ and FRAUMAN AG. Network analysis of an in vitro model of androgen-resistance in prostate cancer. BMC Cancer, 2015; 15:883 doi:10.1186/s12885-015-1884-7.
- Detchokul S and Frauman AG. (2014), Editorial. British Journal of Pharmacology, 171: 5459–5461. doi: 10.1111/bph.12849.
- Detchokul S, Newell B, Williams ED, and Frauman AG. (2014). CD151 is associated with prostate cancer cell invasion and lymphangiogenesis in vivo. Oncology Reports, 31(1), 241-7. doi: 10.3892/or.2013.2823.
- Detchokul S, Williams ED, Parker MW and Frauman AG. (2013). Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. British Journal of Pharmacology, doi: 10.1111/bph.12260 (e-publication May 2013).
- Detchokul S and Frauman AG. (2011). Recent developments in prostate cancer biomarker research: therapeutic implications. British Journal of Clinical Pharmacology, 71(2), 157-174.